Sarepta's Stock Rises on Positive Updates on DM1 Therapy

Key Takeaways Sarepta shares rose after progress on its phase I/II SRP-1003 study for DM1.The company advanced dosing after a positive safety committee review of the program.The update also triggered a $200M milestone payment to Arrowhead under its licensing deal.Shares of Sarepta Therapeutics (SRPT) rose 7% on Monday after the company announced its progress on a phase I/II study evaluating SRP-1003, an investigational small interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1).While Sarep ...